The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
so it went through phase one two okay uh I think there was there was some what was the efficacy in phase two there was some efficacy um in what's the phenotype of this patient without gene therapy is it total blindness as well also blindness or or deteriorating Vision so blind by what age um probably 30s okay wow um they found that there's some improving Vision um but but but I think it wasn't as robust as they had H for okay
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.